Skip to main content
Top
Published in: Medical Oncology 8/2014

01-08-2014 | Original Paper

miR-129-1-3p inhibits cell migration by targeting BDKRB2 in gastric cancer

Authors: Danping Wang, Lin Luo, Junming Guo

Published in: Medical Oncology | Issue 8/2014

Login to get access

Abstract

MicroRNAs (miRNAs) are a class of small noncoding RNAs, which regulate gene expression in the posttranscriptional level. They are involved in cancer occurrence and development. Different members of the same miRNA family may have different roles. Since the fact that metastasis is the main cause of cancer-related death and miR-129 has three members, in this study, we focused on the migration inhibitory role of miR-129-1-3p in gastric cancer and explored the possible mechanisms. We first compared the expression of three miR-129 family members, miR-129-5p, miR-129-1-3p, and miR-129-2-3p, between gastric carcinoma tissues and surgical margin non-cancer samples by quantitative real-time reverse transcription-polymerase chain reaction (QRT-PCR). Then, we selected miR-129-1-3p for further analysis and transfected its mimic and inhibitor into gastric cancer BGC-823 cells, respectively. Then, we compared the BGC-823 cells’ migration capacity by transwell assay. Finally, we predicted the possible targets of miR-129-1-3p and selected one target for further analysis by QRT-PCR and luciferase reporter assay. The results showed that the expression of miR-129-1-3p in gastric carcinoma was significantly lower than that in surgical margin samples. And miR-129-1-3p could inhibit the migration of BGC-823 cells. From the candidates, we selected bradykinin receptor B2 (BDKRB2), which was reported relating to metastasis, as a target for further analysis. QRT-PCR showed that the expression of BDKRB2 was negatively related to miR-129-1-3p. Luciferase reporter assay showed that BDKRB2 was the target of the miR-129-1-3p. In summary, miR-129-1-3p inhibits the BGC-823 cell migration by targeting BDKRB2.
Literature
1.
go back to reference Comen EA. Tracking the seed and tending the soil: evolving concepts in metastatic breast cancer. Discov Med. 2012;14:97–104.PubMed Comen EA. Tracking the seed and tending the soil: evolving concepts in metastatic breast cancer. Discov Med. 2012;14:97–104.PubMed
2.
go back to reference Shi X, Sun M, Liu H, et al. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339:159–66.PubMedCrossRef Shi X, Sun M, Liu H, et al. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339:159–66.PubMedCrossRef
4.
go back to reference Izzotti A, Cartiglia C, Steele VE, et al. MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res. 2012;751:287–303.PubMedCrossRef Izzotti A, Cartiglia C, Steele VE, et al. MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res. 2012;751:287–303.PubMedCrossRef
5.
go back to reference Brest P, Lassalle S, Hofman V, et al. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer. 2011;18:711–9.PubMedCrossRef Brest P, Lassalle S, Hofman V, et al. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer. 2011;18:711–9.PubMedCrossRef
6.
go back to reference Wang QY, Tang J, Zhou CX, et al. The down-regulation of miR-129 in breast cancer and its effect on breast cancer migration and motility. Sheng Li Xue Bao. 2012;64:403–11.PubMed Wang QY, Tang J, Zhou CX, et al. The down-regulation of miR-129 in breast cancer and its effect on breast cancer migration and motility. Sheng Li Xue Bao. 2012;64:403–11.PubMed
7.
go back to reference Liu Y, Hei Y, Shu Q, et al. VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS ONE. 2012;7:e35800.PubMedCentralPubMedCrossRef Liu Y, Hei Y, Shu Q, et al. VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS ONE. 2012;7:e35800.PubMedCentralPubMedCrossRef
8.
go back to reference Yu X, Luo L, Wu Y, et al. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol. 2013;30:365.PubMedCrossRef Yu X, Luo L, Wu Y, et al. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol. 2013;30:365.PubMedCrossRef
9.
go back to reference Karaayvaz M, Zhai H, Ju J. miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis. 2013;4:e659.PubMedCentralPubMedCrossRef Karaayvaz M, Zhai H, Ju J. miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis. 2013;4:e659.PubMedCentralPubMedCrossRef
10.
go back to reference Li M, Tian L, Wang L, et al. Down-regulation of miR-129-5p inhibits growth and induces apoptosis in laryngeal squamous cell carcinoma by targeting APC. PLoS ONE. 2013;8:e77829.PubMedCentralPubMedCrossRef Li M, Tian L, Wang L, et al. Down-regulation of miR-129-5p inhibits growth and induces apoptosis in laryngeal squamous cell carcinoma by targeting APC. PLoS ONE. 2013;8:e77829.PubMedCentralPubMedCrossRef
11.
go back to reference Zhang J, Li S, Yan Q, et al. Interferon-β induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells. PLoS ONE. 2013;8:e81366.PubMedCentralPubMedCrossRef Zhang J, Li S, Yan Q, et al. Interferon-β induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells. PLoS ONE. 2013;8:e81366.PubMedCentralPubMedCrossRef
12.
go back to reference Wu J, Qian J, Li C, et al. miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle. 2010;9:1809–18.PubMedCrossRef Wu J, Qian J, Li C, et al. miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle. 2010;9:1809–18.PubMedCrossRef
13.
go back to reference Shen R, Pan S, Qi S, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun. 2010;394:1047–52.PubMedCrossRef Shen R, Pan S, Qi S, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun. 2010;394:1047–52.PubMedCrossRef
14.
go back to reference Huang HY, Cheng YY, Liao WC, et al. SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer. PLoS ONE. 2012;7:e48637.PubMedCentralPubMedCrossRef Huang HY, Cheng YY, Liao WC, et al. SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer. PLoS ONE. 2012;7:e48637.PubMedCentralPubMedCrossRef
15.
go back to reference Chen X, Zhang L, Zhang T, et al. Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int. 2013;33:476–86.PubMedCrossRef Chen X, Zhang L, Zhang T, et al. Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int. 2013;33:476–86.PubMedCrossRef
16.
go back to reference Yu HS, Lin TH, Tang CH. Involvement of intercellular adhesion molecule-1 up-regulation in bradykinin promotes cell motility in human prostate cancers. Int J Mol Sci. 2013;14:13329–45.PubMedCentralPubMedCrossRef Yu HS, Lin TH, Tang CH. Involvement of intercellular adhesion molecule-1 up-regulation in bradykinin promotes cell motility in human prostate cancers. Int J Mol Sci. 2013;14:13329–45.PubMedCentralPubMedCrossRef
17.
go back to reference Yu HS, Lin TH, Tang CH. Bradykinin enhances cell migration in human prostate cancer cells through B2 receptor/PKCδ/c-Src dependent signaling pathway. Prostate. 2013;73:89–100.PubMedCrossRef Yu HS, Lin TH, Tang CH. Bradykinin enhances cell migration in human prostate cancer cells through B2 receptor/PKCδ/c-Src dependent signaling pathway. Prostate. 2013;73:89–100.PubMedCrossRef
18.
go back to reference Montana V, Sontheimer H. Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci. 2011;11:4858–67.CrossRef Montana V, Sontheimer H. Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci. 2011;11:4858–67.CrossRef
19.
go back to reference Yu X, Song H, Xia T, et al. Growth inhibitory effects of three miR-129 family members on gastric cancer. Gene. 2013;532:87–93.PubMedCrossRef Yu X, Song H, Xia T, et al. Growth inhibitory effects of three miR-129 family members on gastric cancer. Gene. 2013;532:87–93.PubMedCrossRef
20.
go back to reference Vassou D, Notas G, Hatzoglou A, et al. Opioids increase bladder cancer cell migration via bradykinin B2 receptors. Int J Oncol. 2011;39:697–707.PubMed Vassou D, Notas G, Hatzoglou A, et al. Opioids increase bladder cancer cell migration via bradykinin B2 receptors. Int J Oncol. 2011;39:697–707.PubMed
21.
go back to reference Erices R, Corthorn J, Lisboa F, et al. Bradykinin promotes migration and invasion of human immortalized trophoblasts. Reprod Biol Endocrinol. 2011;9:97.PubMedCentralPubMedCrossRef Erices R, Corthorn J, Lisboa F, et al. Bradykinin promotes migration and invasion of human immortalized trophoblasts. Reprod Biol Endocrinol. 2011;9:97.PubMedCentralPubMedCrossRef
22.
go back to reference Jiang J, Liu W, Guo X, et al. IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer. Oncogene. 2011;30:4498–508.PubMedCentralPubMedCrossRef Jiang J, Liu W, Guo X, et al. IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer. Oncogene. 2011;30:4498–508.PubMedCentralPubMedCrossRef
Metadata
Title
miR-129-1-3p inhibits cell migration by targeting BDKRB2 in gastric cancer
Authors
Danping Wang
Lin Luo
Junming Guo
Publication date
01-08-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 8/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0098-1

Other articles of this Issue 8/2014

Medical Oncology 8/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.